Fluid Dynamics in Man of an Intraperitoneal Drug Delivery Solution: 4% Icodextrin
Interest in targeting drugs into the peritoneal cavity for intra-abdominal cancers or infections is undergoing a revival as recent clinical trials have demonstrated, not only a regional advantage in concentration of the active agent, but also improved long-term outcomes. Solutions currently used for...
Saved in:
Published in: | Drug delivery Vol. 8; no. 1; pp. 9 - 12 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
Informa UK Ltd
2001
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Interest in targeting drugs into the peritoneal cavity for intra-abdominal cancers or infections is undergoing a revival as recent clinical trials have demonstrated, not only a regional advantage in concentration of the active agent, but also improved long-term outcomes. Solutions currently used for intraperitoneal (IP) drug delivery have short residence times, however, which can limit the exposure of all areas of the peritoneum to the active agent. Icodextrin 4% solution was compared with saline and a glucose-based peritoneal dialysis solution in a clinical study of IP residence time. The study was carried out during the fortnightly rest phase in 9 patients undergoing 5-fluorouracil (5-Fu) IP treatment for colorectal cancer. The volume remaining in the peritoneal cavity was measured at 0, 12, 24, 48, 72, and 96 hr after an instillation of 2 liters of each fluid. Saline (n = 3 dwells) and glucose (n = 3 dwells) peritoneal dialysis solutions were almost fully absorbed by 24 hr, and the patients experienced discomfort when using these solutions. In contrast, icodextrin 4% solution (n = 188 dwells) maintained its instilled volume for up to 48 hr, and half the instilled volume remained after 72 and 96 hr. This result would allow extensive and prolonged coverage of the peritoneal surface. Icodextrin 4% solution may be an effective vehicle to deliver therapeutic agents into the peritoneal cavity. |
---|---|
AbstractList | Interest in targeting drugs into the peritoneal cavity for intra-abdominal cancers or infections is undergoing a revival as recent clinical trials have demonstrated, not only a regional advantage in concentration of the active agent, but also improved long-term outcomes. Solutions currently used for intraperitoneal (IP) drug delivery have short residence times, however, which can limit the exposure of all areas of the peritoneum to the active agent. Icodextrin 4% solution was compared with saline and a glucose-based peritoneal dialysis solution in a clinical study of IP residence time. The study was carried out during the fortnightly rest phase in 9 patients undergoing 5-fluorouracil (5-Fu) IP treatment for colorectal cancer. The volume remaining in the peritoneal cavity was measured at 0, 12, 24, 48, 72, and 96 hr after an instillation of 2 liters of each fluid. Saline (n = 3 dwells) and glucose (n = 3 dwells) peritoneal dialysis solutions were almost fully absorbed by 24 hr, and the patients experienced discomfort when using these solutions. In contrast, icodextrin 4% solution (n = 188 dwells) maintained its instilled volume for up to 48 hr, and half the instilled volume remained after 72 and 96 hr. This result would allow extensive and prolonged coverage of the peritoneal surface. Icodextrin 4% solution may be an effective vehicle to deliver therapeutic agents into the peritoneal cavity. |
Author | K. Hosie, J. A. Gilbert, D. Kerr, C. B. Brown, E. M. Peers |
Author_xml | – sequence: 1 givenname: K surname: Hosie fullname: Hosie, K organization: Northern General Hospital, Sheffield, United Kingdom – sequence: 2 givenname: J A surname: Gilbert fullname: Gilbert, J A – sequence: 3 givenname: D surname: Kerr fullname: Kerr, D – sequence: 4 givenname: C B surname: Brown fullname: Brown, C B – sequence: 5 givenname: E M surname: Peers fullname: Peers, E M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/11280443$$D View this record in MEDLINE/PubMed |
BookMark | eNplkMtOwzAQRS1URB_wAyyQNywDfsV2EBvUUqhUhBCwjhw_qKvEqZwE0b_HqLBiFjObo5k5dwpGoQ0WgHOMrjCS6BojgUXOEKYoFeEFOwITTDnP8oLIEZggxIpMkpyNwbTrtgnimJATMMaYSMQYnYCXZT14Axf7oBqvO-gDfFIBtg6mvgp9VDsbfZ8Oqxou4vABF7b2nzbu4WtbD71vww1kl3ClW2O_-ujDKTh2qu7s2e-cgffl_dv8MVs_P6zmd-tM50z0GdPEIMa1MJUVFDOhOKJKKOEKpSmpmNNcElZwVMkqJ3mOuHHJRyplHOeYzsDFYe9uqBpryl30jYr78s8tAbcHwAfXxkZtkkK_0SractsOMaTnSozKnyjL_1HSb40WZJk |
CitedBy_id | crossref_primary_10_1007_s00404_010_1423_3 crossref_primary_10_1016_S1525_0016_03_00057_1 crossref_primary_10_1016_j_fertnstert_2016_08_012 crossref_primary_10_1016_j_gmit_2014_01_004 crossref_primary_10_5301_je_5000190 crossref_primary_10_1016_j_rigapp_2006_02_001 crossref_primary_10_1002_14651858_CD011254_pub2 crossref_primary_10_1016_j_ygyno_2006_06_005 crossref_primary_10_3390_jcm11061476 crossref_primary_10_1111_j_1463_1318_2009_02132_x crossref_primary_10_1007_s00464_013_3102_5 crossref_primary_10_1016_S0090_8258_02_00148_8 crossref_primary_10_1308_003588406X114730 crossref_primary_10_1111_j_1463_1318_2007_01357_x crossref_primary_10_1016_j_actbio_2017_08_002 crossref_primary_10_1016_j_fertnstert_2006_12_084 crossref_primary_10_1089_gyn_2010_0084 crossref_primary_10_1016_S1055_3207_03_00039_5 crossref_primary_10_1002_jbm_a_33083 crossref_primary_10_1002_mabi_202000395 crossref_primary_10_1016_j_rigp_2005_04_003 crossref_primary_10_17116_hirurgia2020091116 crossref_primary_10_1016_S0140_6736_13_61687_6 crossref_primary_10_1016_j_jconrel_2018_11_010 crossref_primary_10_1053_ejso_2002_1348 crossref_primary_10_1002_jbm_b_33824 crossref_primary_10_1007_s11605_011_1819_9 crossref_primary_10_1016_j_jss_2018_10_003 crossref_primary_10_1089_gyn_2014_0052 crossref_primary_10_1007_s10397_007_0333_2 crossref_primary_10_3390_medicina58030386 crossref_primary_10_1097_GCO_0b013e3283073a6c crossref_primary_10_2217_fon_09_11 crossref_primary_10_1046_j_1463_1318_2003_00447_x crossref_primary_10_1152_ajprenal_00313_2004 crossref_primary_10_1016_j_actbio_2020_08_036 crossref_primary_10_1158_0008_5472_CAN_05_2691 crossref_primary_10_1002_14651858_CD001298_pub4 crossref_primary_10_1002_14651858_CD001298_pub5 crossref_primary_10_1016_j_ejogrb_2009_12_026 crossref_primary_10_1016_j_pog_2010_07_004 crossref_primary_10_1016_j_ijsu_2013_07_019 crossref_primary_10_1186_1471_2482_13_34 crossref_primary_10_1016_j_progpolymsci_2014_10_004 crossref_primary_10_1097_MS9_0000000000001810 crossref_primary_10_1016_j_ejso_2007_05_007 crossref_primary_10_1111_j_1463_1318_2009_02007_x crossref_primary_10_1155_2013_720858 crossref_primary_10_1016_j_ijsu_2007_05_010 crossref_primary_10_1016_j_suronc_2014_03_004 crossref_primary_10_3748_wjg_14_2179 crossref_primary_10_1016_j_ejpb_2007_03_027 crossref_primary_10_1515_pp_2017_0002 crossref_primary_10_1016_j_fertnstert_2006_05_023 crossref_primary_10_1590_S0101_98802006000200014 crossref_primary_10_1016_j_canlet_2008_07_024 crossref_primary_10_1093_humupd_dml061 crossref_primary_10_1016_S0022_4804_03_00162_8 |
ContentType | Journal Article |
Copyright | 2001 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2001 |
Copyright_xml | – notice: 2001 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2001 |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1080/107175401300002694 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1366-5928 |
EndPage | 12 |
ExternalDocumentID | 11280443 10_1080_107175401300002694 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .GJ 00X 03L 0BK 0R~ 123 29R 36B 4.4 53G 5RE 5VS AACCU AAJNR AALIY AALUX AAMIU AAPUL AAPXX AAQRR ABBKH ABCRQ ABDBF ABEIZ ABLKL ABPTK ABUPF ACENM ACFUF ACGEJ ACGFS ACLSK ADCVX ADFCX ADRBQ ADXPE AECIN AEGXH AENEX AEOZL AEYQI AFAUU AFKVX AFQCT AFWLO AGAFX AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJEBJ AJWEG AJXHO AKBVH ALIIL ALMA_UNASSIGNED_HOLDINGS ALQZU AWYRJ BABNJ BLEHA BOHLJ BVLLS CAG CCCUG COF CS3 DEIEU DKSSO DLVIE DTRLO DU5 DZHFC EAP EBC EBD EBS EBX EDH EJD EMB EMK EMOBN EPL ESX F5P H13 HZ~ J.N JFOCU KRBQP KWAYT KYCEM L7B LJTGL M44 M4Z MK0 O9- OVD QRXOQ RNANH RVRKI SV3 TEORI TFDNU TFL TFW TUS UHWXJ V1S ZGI ZXP ~1N ~KM 0VX 0YH 29G 5GY 7X7 88I 8FI 8FJ ABUWG ADBBV AFKRA ALIPV AOIJS ARJSQ AZQEC BCNDV BENPR BPHCQ BVXVI CCPQU CGR CUY CVF DWQXO ECM EIF FYUFA GNUQQ GROUPED_DOAJ HCIFZ HMCUK HYE M2P NPM OK1 P2P PIMPY PQQKQ PROAC RPM TDBHL UKHRP |
ID | FETCH-LOGICAL-c547t-4c2d046c7dbe73147a603a7a7f9ac32b4fc6824960b8b525506df0498aadf6613 |
ISSN | 0049-8254 1071-7544 |
IngestDate | Sat Sep 28 08:38:41 EDT 2024 Tue Jul 04 19:21:03 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c547t-4c2d046c7dbe73147a603a7a7f9ac32b4fc6824960b8b525506df0498aadf6613 |
OpenAccessLink | https://www.tandfonline.com/doi/pdf/10.1080/107175401300002694?needAccess=true |
PMID | 11280443 |
PageCount | 4 |
ParticipantIDs | pubmed_primary_11280443 informahealthcare_journals_10_1080_107175401300002694 |
PublicationCentury | 2000 |
PublicationDate | 20010000 2001 Jan-Mar |
PublicationDateYYYYMMDD | 2001-01-01 |
PublicationDate_xml | – year: 2001 text: 20010000 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Drug delivery |
PublicationTitleAlternate | Drug Deliv |
PublicationYear | 2001 |
Publisher | Informa UK Ltd |
Publisher_xml | – name: Informa UK Ltd |
SSID | ssj0006122 ssj0008125 |
Score | 1.8878134 |
Snippet | Interest in targeting drugs into the peritoneal cavity for intra-abdominal cancers or infections is undergoing a revival as recent clinical trials have... |
SourceID | pubmed informahealthcare |
SourceType | Index Database Publisher |
StartPage | 9 |
SubjectTerms | Aged Aged, 80 and over Antimetabolites, Antineoplastic - administration & dosage Colorectal Neoplasms - drug therapy Dialysis Solutions - administration & dosage Drug Delivery Systems Female Fluorouracil - administration & dosage Glucans - administration & dosage Glucose - administration & dosage Humans Icodextrin Kidney - drug effects Kidney Function Tests Male Middle Aged Peritoneal Dialysis Water-Electrolyte Balance |
Title | Fluid Dynamics in Man of an Intraperitoneal Drug Delivery Solution: 4% Icodextrin |
URI | https://www.ncbi.nlm.nih.gov/pubmed/11280443 |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Pb9MwFLZYdwAOaAwY48fkA9slS5TETuJwK23GoOpURCftViW2A5WmgtL2sP-e92InqRYhARJSFFVWZSV-X5_9ud_7TMg7DcxEBTJwZSBTICiSuUJE0uUFStfCMhE-ViNffk2ubsQ441m3mdO1_ddIQxvEGitn_yLabafQAJ8h5nCHqMP9j-J-cbtdKmdsDpqvxa7TvF4S5vX2HxZbVUt04MZ8V22_Qca5RW0G5BD7XLhJwE_DyPlU17tvKmvObZewN3qF1k2bHZHPxMPzR8w_HZ89Z-g5H5fonVUn-LHnTHRlyg095wNcDfPPPGfqOTNtRfjt5kO37dAUS11PduRHdYblqYus08wvJqmyOHaj1BaB26wreuAyGTTdmYqNwLqX5I0qMkAmGiE9xDkXC3K7Ka0VGgbWAbX_5T2yH0Ju4gOyPxxlV9N2-oYln7GYty9iK63QfrPfy2NyYA1uv7dyvXsEpV6ozA_IE8sw6NBA4yl5oFeH5OGoOdjvkJzNjF353Tmdd9V363N6RmedkfndM_KlxhJtsESXKwpYoj9KCvd7WKKIJdpgiTZYek_5Ke1w9JxcX2Tz0aVrj-BwZcSTjctlqHwey0QVOmEBT_LYZ3mSJ2WaSxYWvJSxAAYf-4UoIqCnfqxKGDmR56qEpR97QQYreIyXhBZpUapYqaBUEY8FFzrQYQHdsVBLlrNjEvWGcmF_WOvF7wN5TI7McC9-Gn8WILWh8Dlnr_6xx9fkkVEa4vWGDDbVVr8le2u1PbFgOQHaNZr-ArVyer8 |
link.rule.ids | 315,782,786,4030,27934,27935,27936,61278,61459 |
linkProvider | Taylor & Francis |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8JAEJ4oHNCDIr7wuQflRJO2u20XL4bwCEQgGDHxRtrdrpKQaigc-PfO0hYS8aRJ096mm93ZmfkmM98A3IWITKQlLENYooYARVCDc0cYLNCla7byuKm7kTsv3uCNN1uaJucx64XRZZUaQ6uEKGJlq_Xl1snorCQOvwhCHI0MtLnVvZi7kEc_46Ba5-uN1qC_NsbowBPCcFYzNBhK-2Z-l7IPxZSu9GNdfPUj3Fy5nfbhvxdchIM04iT1REWOYCeMSlBoZIPeSlAZJvTVyyoZbbqx4iqpkOGG2Hp5DM_t6WIiSTMZYh-TSUT6fkQ-FcF3V2eJNW2yZvfG_zVni3fSDKe67mNJsuzbA2H3pLvqo5_PJtEJvLZbo0bHSEcyGMJh3txgwpaIqIUng9CjFvN816S-53uq5gtqB0wJlyOic82ABw7CFdOVCvee-75UGArQU8hFuIxzIEEtUNKV0lLSYS5nPLRCO0Bx1A4F9WkZnK3DGKcXLB5bKbXp9s6W4Sw5sPFXwteBIMfmJmP04o8Sb6HQGfV741538HQJe0kVmn6uIDefLcJr2I3l4iZVvW96tNW5 |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba8IwFD5MhV0eNudu7pqHzScLbZM2cQ8DsRZlUxxzsDdpk2YTpBO1D_77JbZV2Pa0QWkhD6chl5PzhfN9B-A2UshEWNwyuMUbCqBwbDDmcIOEOnXNlpSZmo3ceaH9N-a1tUzOQ86F0WmVGkPLVChi5av15p4KmWfEqa_CII4GBtrbaipmAUrqpKasCKVmq93vrX2xak31wknD0Fgoo838bmUPypla6cc69-pbtLk6dfyD__a3DPtZvIma6QI5hK0orsBOKy_zVoHaIBWvXtbRcMPFmtdRDQ02stbLI3j2J8lYIC8tYT9H4xj1ghh9SqTeXX1HrEWTtba3-p83S96RF0101scS5Xdv94jcoe6KRb-YjeNjePXbw1bHyAoyGNwhdGEQbguFpzkVYUSxRWjgmjigAZWNgGM7JJK7TOE51wxZ6CiwYrpCqqFnQSCkCgTwCRRj1Y0zQGEjlMIVwpLCIS4jLLIiO1TmsB1xHOAqOD_mYpRtr_nIyoRNf45sFU7T-RpNU7UOBXFsZhKCz_9o8Qa2B54_eur2Hy9gN01B088lFBezJLqCwlwk19nC-wIN1dRo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fluid+Dynamics+in+Man+of+an+Intraperitoneal+Drug+Delivery+Solution%3A+4%25+Icodextrin&rft.jtitle=Xenobiotica&rft.au=K.+Hosie%2C+J.+A.+Gilbert%2C+D.+Kerr%2C+C.+B.+Brown%2C+E.+M.+Peers&rft.date=2001&rft.pub=Informa+UK+Ltd&rft.issn=0049-8254&rft.eissn=1366-5928&rft.volume=8&rft.issue=1&rft.spage=9&rft.epage=12&rft_id=info:doi/10.1080%2F107175401300002694&rft.externalDocID=10_1080_107175401300002694 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0049-8254&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0049-8254&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0049-8254&client=summon |